Issued 2026-09-25 at $526.19 · now $526.19 (2026-09-25, +0.0% since)
Based on its own history, a month from the 2026-09-25 close, VRTX has typically landed between $478.64 and $594.80 — a range of −9.0% to +13.0% from the issuance price $526.19.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,692 overlapping 1 month windows · 2008-01-02 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.
The cone is anchored at the 2026-09-25 issuance close ($526.19) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where VRTX has typically landed a month from the 2026-09-25 close of $526.19 — the range is history, not a prediction.
- now $526.19 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $536.64 (+2.0%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $513.57–$559.71
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $478.64–$594.8
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,692 windows spanning 2008-01-02 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2011-10-26 | −38.0% | −38.0% | +0.0% |
| 2011-10-25 | −37.8% | −37.8% | +0.0% |
| 2008-09-26 | −37.4% | −38.1% | +0.0% |
| 3 best | |||
| 2008-03-10 | +81.6% | +0.0% | +81.6% |
| 2012-04-13 | +78.9% | −1.9% | +78.9% |
| 2012-04-16 | +78.6% | +0.0% | +82.3% |
4,692 overlapping windows · 2008-01-02 – 2026-09-25 · not cherry-picked
Pending catalysts
- 2026-10-30 — Trial primary completion: Phase 3 primary completion: A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy (source, as of 2026-08-14)
- 2026-12-30 — Trial primary completion: Phase 2 primary completion: Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities (source, as of 2026-08-14)
- 2027-01-25 — Trial primary completion: Phase 3 primary completion: Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) (source, as of 2026-08-14)
- 2027-02-02 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (source, as of 2026-08-14)
- 2027-03-12 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes (source, as of 2026-08-14)
- 2027-03-25 — Trial primary completion: Phase 2 primary completion: Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy (source, as of 2026-08-14)
- 2027-04-06 — Trial primary completion: Phase 3 primary completion: Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del (source, as of 2026-08-14)
- 2027-04-06 — Trial primary completion: Phase 3 primary completion: Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy (source, as of 2026-08-14)
- 2027-05-31 — Trial primary completion: Phase 3 primary completion: Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (source, as of 2026-08-14)
- 2027-06-06 — Trial primary completion: Phase 3 primary completion: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) (source, as of 2026-08-14)
- 2027-06-09 — Trial primary completion: Phase 3 primary completion: Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease (source, as of 2026-08-14)
- 2027-06-30 — Trial primary completion: Phase 3 primary completion: A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Fundamentals iCompany financials — revenue, earnings, margins — from the newest filings shown, each carried with its date.iAs-reported figures and standard ratios from FMP, as of 2026-07-25. Revenue, net income and free cash flow can toggle annual or quarterly; margin, ROE and debt-to-equity are shown by fiscal year. We report the figures and the trend — no target price and no over/under-valued call. More on /methodology.
$121.2B
market cap
$16.86
EPS (TTM)
28.3
P/E (TTM)
2026-08-03
next earnings
Revenue$12.1B
'20'25
Net income$4.0B
'20'25
Free cash flow$3.2B
'20'25
Net margin · by yr32.7%
'20'25
ROE · by yr21.2%
'20'25
Debt / equity · by yr0.21
'20'25
Fair value — three views iIndependent reference estimates of worth (a cash-flow model, peer multiples, analyst targets), shown as separate views — not a single verdict.
iThree independent estimates of per-share value, each by a different method and each with its own assumptions: a discounted-cash-flow intrinsic value, a peer comparable (the median trailing P/E of 54 sector peers times this company's trailing EPS), and the analyst price-target consensus. They routinely disagree — that gap is the point. We show the three marks and the current price; we do not blend them into a single number or call the stock over- or under-valued. Marks as of the latest capture. More on /methodology.- DCF (intrinsic)$392.63
- Peer P/E × EPS · sector median 27.4× · n=54$462.65
- Analyst target · range $350.00–$616.00$576.00
- Current price · last close 2026-09-25$526.19
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~19 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Jan
78%
+5.0%
n=18
Feb
47%
+0.2%
n=19
Mar
58%
+3.9%
n=19
Apr
63%
+3.8%
n=19
May
58%
+4.9%
n=19
Jun
63%
+4.9%
n=19
Jul
53%
+0.9%
n=19
Aug
53%
−0.6%
n=19
Sep
47%
+0.1%
n=19
Oct
50%
−2.5%
n=18
Nov
56%
−0.4%
n=18
Dec
67%
+3.7%
n=18
Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | McKechnie Duncan | officer | Sale | 1,541 @ $519.00 | $800K | −12.3% of holding | −12.6% | not yet — horizon still open | 11,001 | Form 4 · filed 5 days after the trade |
| 2026-07-02 | Tatsis Ourania | director | Sale | 1,500 @ $524.99 | $787K | −3.2% of holding | −12.6% | not yet — horizon still open | 45,321 | Form 4 · filed 5 days after the trade |
| 2026-07-01 | Liu Joy | officer | Sale | 828 @ $502.71 | $416K | −4.1% of holding | −4.4% | not yet — horizon still open | 19,131 | Form 4 · filed 5 days after the trade |
| 2026-06-26 | Bozic Carmen | officer | Sale | 596 @ $482.50 | $288K | −3.7% of holding | −1.8% | not yet — horizon still open | 15,337 | Form 4 · filed 4 days after the trade |
| 2026-06-18 | Bozic Carmen | officer | Sale | 1,020 @ $462.17 | $471K | −6.0% of holding | +6.5% | not yet — horizon still open | 15,933 | Form 4 · filed 5 days after the trade |
| 2026-06-15 | Bozic Carmen | officer | Sale | 4,062 @ $450.00 | $1.8M | −19.3% of holding | +8.2% | not yet — horizon still open | 16,953 | Form 4 · filed 2 days after the trade |
| 2026-06-05 | Bozic Carmen | officer | Sale | 1,745 @ $450.00 | $785K | −7.7% of holding | +10.2% | not yet — horizon still open | 21,015 | Form 4 · filed 4 days after the trade |
| 2026-06-01 | Liu Joy | officer | Sale | 828 @ $439.91 | $364K | −4.0% of holding | +15.0% | not yet — horizon still open | 19,959 | Form 4 · filed 2 days after the trade |
| 2026-05-29 | Bozic Carmen | officer | Sale | 1,974 @ $450.00 | $888K | −8.0% of holding | +12.0% | not yet — horizon still open | 22,760 | Form 4 · filed 4 days after the trade |
| 2026-05-15 | Bozic Carmen | officer | Sale | 1,354 @ $453.45 | $614K | −5.2% of holding | +2.2% | not yet — horizon still open | 24,734 | Form 4 · filed 4 days after the trade |
| 2026-05-15 | Bunnage Mark E. | officer | Sale | 33 @ $453.45 | $15K | −0.5% of holding | +2.2% | not yet — horizon still open | 7,284 | Form 4 · filed 4 days after the trade |
| 2026-05-12 | Bozic Carmen | officer | Sale | 6,988 @ $450.00 | $3.1M | −21.1% of holding | −0.7% | not yet — horizon still open | 26,088 | Form 4 · filed 2 days after the trade |
| 2026-05-04 | Bhatia Sangeeta N. | director | Sale | 318 @ $423.73 | $135K | −6.1% of holding | −5.4% | not yet — horizon still open | 4,924 | Form 4 · filed 1 day after the trade |
| 2026-05-01 | Liu Joy | officer | Sale | 1,104 @ $425.02 | $469K | −5.1% of holding | −5.1% | not yet — horizon still open | 20,729 | Form 4 · filed 4 days after the trade |
| 2026-04-01 | Liu Joy | officer | Sale | 978 @ $449.17 | $439K | −4.3% of holding | −15.2% | not yet — horizon still open | 21,833 | Form 4 · filed 2 days after the trade |
| 2026-03-27 | Bozic Carmen | officer | Sale | 2,329 @ $450.95 | $1.1M | −6.6% of holding | −12.9% | not yet — horizon still open | 33,076 | Form 4 · filed 4 days after the trade |
| 2026-03-13 | Bozic Carmen | officer | Sale | 2,329 @ $481.79 | $1.1M | −6.2% of holding | −10.5% | −4.5% | 35,405 | Form 4 · filed 4 days after the trade |
| 2026-03-11 | McKechnie Duncan | officer | Sale | 2,633 @ $498.42 | $1.3M | −17.4% of holding | −12.1% | −8.1% | 12,489 | Form 4 · filed 2 days after the trade |
| 2026-03-04 | McKechnie Duncan | officer | Sale | 2,437 @ $475.30 | $1.2M | −13.9% of holding | −4.2% | +4.2% | 15,122 | Form 4 · filed 2 days after the trade |
| 2026-03-02 | Liu Joy | officer | Sale | 892 @ $495.96 | $442K | −3.8% of holding | −3.1% | −0.3% | 22,811 | Form 4 · filed 2 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 15,580 @ $495.38 | $7.7M | −12.8% of holding | −3.2% | −3.7% | 105,998 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 5,995 @ $496.16 | $3.0M | −5.7% of holding | −3.2% | −3.7% | 100,003 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 3,498 @ $494.33 | $1.7M | −2.8% of holding | −3.2% | −3.7% | 121,578 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 3,278 @ $488.27 | $1.6M | −2.4% of holding | −3.2% | −3.7% | 131,730 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 2,725 @ $490.54 | $1.3M | −2.1% of holding | −3.2% | −3.7% | 128,545 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 2,520 @ $493.29 | $1.2M | −2.0% of holding | −3.2% | −3.7% | 125,076 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 2,510 @ $487.13 | $1.2M | −1.8% of holding | −3.2% | −3.7% | 135,008 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Bozic Carmen | officer | Sale | 2,329 @ $480.31 | $1.1M | −5.8% of holding | −3.2% | −3.7% | 37,734 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 1,725 @ $496.95 | $857K | −1.7% of holding | −3.2% | −3.7% | 98,278 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 949 @ $491.30 | $466K | −0.7% of holding | −3.2% | −3.7% | 127,596 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 460 @ $489.32 | $225K | −0.3% of holding | −3.2% | −3.7% | 131,270 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 400 @ $479.75 | $192K | −0.3% of holding | −3.2% | −3.7% | 137,878 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 240 @ $482.84 | $116K | −0.2% of holding | −3.2% | −3.7% | 137,518 | Form 4 · filed 4 days after the trade |
| 2026-02-27 | Kewalramani Reshma | director | Sale | 120 @ $481.50 | $58K | −0.1% of holding | −3.2% | −3.7% | 137,758 | Form 4 · filed 4 days after the trade |
| 2026-02-26 | Ambrose Kristen | officer | Sale | 357 @ $483.36 | $173K | −5.1% of holding | −2.0% | +1.6% | 6,624 | Form 4 · filed 4 days after the trade |
| 2026-02-25 | McKechnie Duncan | officer | Sale | 2,500 @ $486.35 | $1.2M | −11.1% of holding | +0.6% | +2.2% | 19,969 | Form 4 · filed 1 day after the trade |
| 2026-02-25 | McKechnie Duncan | officer | Sale | 2,410 @ $489.00 | $1.2M | −12.1% of holding | +0.6% | +2.2% | 17,559 | Form 4 · filed 1 day after the trade |
| 2026-02-25 | Sachdev Amit | officer | Sale | 1,846 @ $486.35 | $898K | −3.2% of holding | +0.6% | +2.2% | 55,570 | Form 4 · filed 1 day after the trade |
| 2026-02-25 | Biller Jonathan | officer | Sale | 945 @ $486.35 | $460K | −6.5% of holding | +0.6% | +2.2% | 13,659 | Form 4 · filed 1 day after the trade |
| 2026-02-25 | Atkinson Edward Morrow III | director | Sale | 668 @ $486.35 | $325K | −3.5% of holding | +0.6% | +2.2% | 18,432 | Form 4 · filed 1 day after the trade |
| 2026-02-25 | Bunnage Mark E. | officer | Sale | 620 @ $486.35 | $302K | −7.8% of holding | +0.6% | +2.2% | 7,284 | Form 4 · filed 1 day after the trade |
| 2026-02-25 | Tatsis Ourania | director | Sale | 260 @ $486.35 | $126K | −0.6% of holding | +0.6% | +2.2% | 46,763 | Form 4 · filed 1 day after the trade |
| 2026-02-25 | Ambrose Kristen | officer | Sale | 223 @ $486.35 | $108K | −3.1% of holding | +0.6% | +2.2% | 6,981 | Form 4 · filed 1 day after the trade |
| 2026-02-19 | Sachdev Amit | officer | Sale | 19,662 @ $468.57 | $9.2M | −19.3% of holding | +1.7% | +3.1% | 82,124 | Form 4 · filed 4 days after the trade |
| 2026-02-19 | Sachdev Amit | officer | Sale | 11,712 @ $470.54 | $5.5M | −15.6% of holding | +1.7% | +3.1% | 63,171 | Form 4 · filed 4 days after the trade |
| 2026-02-19 | Sachdev Amit | officer | Sale | 10,263 @ $467.75 | $4.8M | −9.2% of holding | +1.7% | +3.1% | 101,786 | Form 4 · filed 4 days after the trade |
| 2026-02-19 | Sachdev Amit | officer | Sale | 7,241 @ $469.61 | $3.4M | −8.8% of holding | +1.7% | +3.1% | 74,883 | Form 4 · filed 4 days after the trade |
| 2026-02-19 | Sachdev Amit | officer | Sale | 4,237 @ $471.43 | $2.0M | −6.7% of holding | +1.7% | +3.1% | 58,934 | Form 4 · filed 4 days after the trade |
| 2026-02-19 | Sachdev Amit | officer | Sale | 2,730 @ $465.05 | $1.3M | −2.3% of holding | +1.7% | +3.1% | 113,897 | Form 4 · filed 4 days after the trade |
| 2026-02-19 | Sachdev Amit | officer | Sale | 1,848 @ $465.80 | $861K | −1.6% of holding | +1.7% | +3.1% | 112,049 | Form 4 · filed 4 days after the trade |
| 2026-02-19 | Sachdev Amit | officer | Sale | 920 @ $463.91 | $427K | −0.8% of holding | +1.7% | +3.1% | 116,627 | Form 4 · filed 4 days after the trade |
| 2026-02-18 | Biller Jonathan | officer | Sale | 1,244 @ $473.68 | $589K | −7.3% of holding | +1.3% | +4.7% | 15,748 | Form 4 · filed 1 day after the trade |
| 2026-02-18 | Bunnage Mark E. | officer | Sale | 1,182 @ $473.68 | $560K | −12.2% of holding | +1.3% | +4.7% | 8,486 | Form 4 · filed 1 day after the trade |
| 2026-02-18 | Atkinson Edward Morrow III | director | Sale | 817 @ $473.68 | $387K | −3.8% of holding | +1.3% | +4.7% | 20,727 | Form 4 · filed 1 day after the trade |
| 2026-02-18 | Ambrose Kristen | officer | Sale | 638 @ $473.68 | $302K | −7.6% of holding | +1.3% | +4.7% | 7,750 | Form 4 · filed 1 day after the trade |
| 2026-02-18 | Tatsis Ourania | director | Sale | 368 @ $473.68 | $174K | −0.8% of holding | +1.3% | +4.7% | 48,650 | Form 4 · filed 1 day after the trade |
| 2026-02-17 | Biller Jonathan | officer | Sale | 2,476 @ $489.46 | $1.2M | −12.7% of holding | −2.3% | −2.3% | 16,992 | Form 4 · filed 2 days after the trade |
| 2026-02-17 | Bunnage Mark E. | officer | Sale | 2,437 @ $489.46 | $1.2M | −20.1% of holding | −2.3% | −2.3% | 9,668 | Form 4 · filed 2 days after the trade |
| 2026-02-17 | Atkinson Edward Morrow III | director | Sale | 2,031 @ $489.46 | $994K | −8.6% of holding | −2.3% | −2.3% | 21,544 | Form 4 · filed 2 days after the trade |
| 2026-02-17 | Ambrose Kristen | officer | Sale | 1,557 @ $489.46 | $762K | −15.7% of holding | −2.3% | −2.3% | 8,388 | Form 4 · filed 2 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
182 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | van Grunsven Jasper | officer | Award / grant | 8,682 | 8,682 | Form 4 |
| 2026-08-28 | Ambrose Kristen | officer | Award / grant | 5,000 | 11,624 | Form 4 |
| 2026-08-27 | SACHS BRUCE I | director | Gift | 6,000 | 39,000 | Form 4 |
| 2026-07-21 | Tatsis Ourania | director | Award / grant | 8,251 | 53,572 | Form 4 |
| 2026-07-21 | Sachdev Amit | officer | Award / grant | 8,251 | 66,512 | Form 4 |
| 2026-07-15 | SACHS BRUCE I | director | Award / grant | 100 | 15,772 | Form 4 |
| 2026-07-15 | Garber Alan M | director | Award / grant | 32 | 65 | Form 4 |
| 2026-05-01 | Garber Alan M | director | Award / grant | 472 | 7,344 | Form 4 |
| 2026-05-01 | CARNEY LLOYD | director | Award / grant | 2,866 | 2,866 | Form 4 |
| 2026-05-01 | Thornberry Nancy | director | Award / grant | 472 | 2,507 | Form 4 |
| 2026-05-01 | Thornberry Nancy | director | Award / grant | 1,433 | 1,433 | Form 4 |
| 2026-05-01 | Bhatia Sangeeta N. | director | Award / grant | 943 | 5,242 | Form 4 |
| 2026-05-01 | Upadhyay Suketu | director | Award / grant | 2,866 | 2,866 | Form 4 |
| 2026-05-01 | Garber Alan M | director | Award / grant | 1,433 | 1,433 | Form 4 |
| 2026-05-01 | Lagarde Michel | director | Award / grant | 2,866 | 2,866 | Form 4 |
| 2026-05-01 | MCKENZIE DIANA | director | Award / grant | 943 | 3,174 | Form 4 |
| 2026-05-01 | SACHS BRUCE I | director | Award / grant | 2,866 | 2,866 | Form 4 |
| 2026-05-01 | Schneider Jennifer | director | Award / grant | 472 | 2,190 | Form 4 |
| 2026-05-01 | Schneider Jennifer | director | Award / grant | 1,433 | 1,433 | Form 4 |
| 2026-05-01 | Upadhyay Suketu | director | Award / grant | 796 | 3,595 | Form 4 |
| 2026-05-01 | Thornberry Nancy | director | Disposition | 398 | 2,109 | Form 4 |
| 2026-05-01 | Schneider Jennifer | director | Award / grant | 796 | 796 | Form 4 |
| 2026-05-01 | Thornberry Nancy | director | Disposition | 398 | 2,109 | Form 4 |
| 2026-05-01 | Thornberry Nancy | director | Award / grant | 398 | 398 | Form 4 |
| 2026-05-01 | Upadhyay Suketu | director | Disposition | 796 | 1,558 | Form 4 |
| 2026-05-01 | Upadhyay Suketu | director | Award / grant | 796 | 3,595 | Form 4 |
| 2026-05-01 | MCKENZIE DIANA | director | Disposition | 796 | 2,378 | Form 4 |
| 2026-05-01 | MCKENZIE DIANA | director | Award / grant | 796 | 7,787 | Form 4 |
| 2026-05-01 | MCKENZIE DIANA | director | Disposition | 796 | 2,378 | Form 4 |
| 2026-05-01 | MCKENZIE DIANA | director | Award / grant | 796 | 7,787 | Form 4 |
| 2026-05-01 | Schneider Jennifer | director | Disposition | 796 | 1,394 | Form 4 |
| 2026-05-01 | Schneider Jennifer | director | Award / grant | 796 | 796 | Form 4 |
| 2026-05-01 | Thornberry Nancy | director | Award / grant | 398 | 398 | Form 4 |
| 2026-05-01 | Upadhyay Suketu | director | Disposition | 796 | 1,558 | Form 4 |
| 2026-05-01 | Schneider Jennifer | director | Disposition | 796 | 1,394 | Form 4 |
| 2026-04-15 | SACHS BRUCE I | director | Award / grant | 107 | 15,672 | Form 4 |
| 2026-04-15 | Upadhyay Suketu | director | Award / grant | 81 | 2,799 | Form 4 |
| 2026-04-15 | Garber Alan M | director | Award / grant | 34 | 34 | Form 4 |
| 2026-02-24 | Kewalramani Reshma | director | Withheld for tax | 4,981 | 138,278 | Form 4 |
| 2026-02-24 | LEIDEN JEFFREY M | director | Withheld for tax | 3,547 | 34,797 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures iStock trades disclosed by members of Congress for this company, by the date they were filed.iDisclosures shown as facts. A purchase “cluster” (≥2 members of Congress filing a buy within 90 days) has historically preceded modestly higher forward returns — and it persisted out-of-sample, though it roughly halved after 2021 (see below). A descriptive historical tendency, not a signal to trade and not used in our forecast. See /methodology.
As of 2026-09-25 · point-in-time by filed date
Purchase clusters · 2015–2021 (dev)+45 bp/mo vs baseline · up-rate 59.3% vs 57.3% · n=31,607 cluster ticker-weeks
Purchase clusters · 2022–2026 (out-of-sample)+32 bp/mo vs baseline · up-rate 54.0% vs 53.3% · n=27,793
A cluster = ≥2 members of Congress filing a purchase within 90 days. The historical tilt persisted after 2021 but roughly halved (+45 → +32 bp/mo forward 1-month vs the S&P 500 weekly-grid baseline). Descriptive historical tendency — not a signal to trade, and not used in our forecast (audition-log 2026-07-27, recomputed 2026-09-08).
| Member | Chamber | Type | Filed | Traded | Size |
|---|---|---|---|---|---|
| Alan Armstrong | Senate | purchase | 2026-07-21 | 2026-03-27 | $1–15K |
| David J. Taylor | House | sale | 2026-02-02 | 2026-01-29 | $1–15K |
| Julia Letlow | House | purchase | 2026-01-13 | 2024-10-23 | $1–15K |
| David J. Taylor | House | purchase | 2025-09-02 | 2025-08-07 | $1–15K |
| Lisa Mcclain | House | sale | 2025-08-13 | 2025-06-11 | $1–15K |
| Lisa Mcclain | House | purchase | 2025-08-13 | 2024-12-11 | $1–15K |
| Lisa Mcclain | House | sale | 2025-08-13 | 2025-06-10 | $1–15K |
| Jefferson Shreve | House | sale | 2025-06-22 | 2025-05-12 | $15–50K |
| Byron Donalds | House | sale | 2025-04-14 | 2025-03-20 | $1–15K |
| Byron Donalds | House | sale | 2025-04-14 | 2025-03-20 | $1–15K |
| Jefferson Shreve | House | purchase | 2025-04-11 | 2025-03-13 | $15–50K |
| Jefferson Shreve | House | purchase | 2025-03-09 | 2025-02-24 | $15–50K |
| Tommy Tuberville | Senate | sale | 2024-06-14 | 2024-05-03 | $1–15K |
| HON. GREG STANTON | House | sale | 2023-11-09 | 2023-10-24 | $1–15K |
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.